14 results on '"Yan, Hua-Zheng"'
Search Results
2. Exosomes derived from vMIP-II-Lamp2b gene-modified M2 cells provide neuroprotection by targeting the injured spinal cord, inhibiting chemokine signals and modulating microglia/macrophage polarization in mice
- Author
-
Fu, Gui-Qiang, Wang, Yang-Yang, Xu, Yao-Mei, Bian, Ming-Ming, Zhang, Lin, Yan, Hua-Zheng, Gao, Jian-Xiong, Li, Jing-Lu, Chen, Yu-Qing, Zhang, Nan, Ding, Shu-Qin, Wang, Rui, Li, Jiang-Yan, Hu, Jian-Guo, and Lü, He-Zuo
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical characteristic of familial exudative vitreous retinopathy occurring in premature infants
- Author
-
Jin-Rong Li, Qi Zhang, Yan-Hua Zheng, Xiao-Chun Mao, and Jing-Jing Li
- Subjects
familial exudative vitreoretinopathy ,retinopathy of prematurity ,avascular zone ,retinal vascular zone ,fluorescein angiograms ,Ophthalmology ,RE1-994 - Abstract
AIM: To describe the clinical characteristics of 6 premature infants diagnosed as familial exudative vitreoretinopathy(FEVR).METHODS: From August 2018 to January 2019, the researchers collected six premature cases of FEVR from Xinhua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine. All 6 infants born prematurely had examinations of fundus photography and fluorescein angiograms under anesthesia. Medical history and angiographic features were analyzed retrospectively.RESULTS: Six infants born prematurely were initially misdiagnosed as retinopathy of prematurity ROP. All underwent injection anti-vascular endothelial growth factor(anti-VEGF)drug into vitreous body cavity subsequently, two of whom were treated with injection anti-VEGF drug into vitreous body cavity twice. Six infants born prematurely had follow-up examinations of fundus photography and fluorescein angiograms with the machine of Retcam digital imaging system under anesthesia, they were eventually diagnosed as FEVR. Then 2 cases were treated with laser photocoagulation, 1 case was treated with injection anti-VEGF drug into vitreous body cavity combined laser photocoagulation, 1 case was treated with injection anti-VEGF drug into vitreous body cavity, 2 cases maintain the follow-up visit. CONCLUSION: Clinically, premature infants FEVR, tend to be misdiagnosed as ROP initially. If the demarcation line separating the avascular from the vascular retinal regions presents persistent or the condition turns to be worse, more examinations will be required to confirm the diagnosis such as fluorescein angiograms under anesthesia. FEVR is a lifelong disease, its symptoms, if present, typically take a progressive course during childhood and adolescence. Early diagnosis of FEVR is crucial due to its progressive nature and the genetic/familial underpinnings of the condition. The correct identification of those FEVR patients can help them receive timely treatment and genetic counseling for those of child-bearing age.
- Published
- 2022
- Full Text
- View/download PDF
4. Primary lymphoma of bone: a population-based study of 2558 patients
- Author
-
Chen-Xin Liu, Tian-Qi Xu, Li Xu, Pan-Pan Wang, Chun Cao, Guang-Xun Gao, and Yan-Hua Zheng
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background: Primary lymphoma of bone (PLB) is an extremely rare malignancy arising in the skeletal system. There is no consensus over the best definition of PLB. Most of the published articles are single-institutional retrospective studies with a limited sample size. The rarity of PLB and discrepancies on diagnostic criteria has resulted in a vague understanding of PLB. Methods We retrospectively analyzed the clinical characteristics and prognostic factors of 2558 PLB patients who were registered in the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2016. Survival rates were calculated using the Kaplan–Meier method. The effects of various factors on survival outcomes were analyzed by using the log-rank test. Univariate and multivariate analyses were conducted by using the Cox proportional hazards model to determine independent prognostic factors. Results: The median follow-up time of all eligible patients was 58 months. There seemed no sex preponderance in PLB incidence. The most involved sites are axial skeletons. The most common histological subtype was diffuse large B-cell lymphoma. The 3-, 5-, 10-, and 20-year overall survival (OS) rates were 70.70%, 65.70%, 54.40% and 39.50%, respectively. PLB patients whose primary tumor sites were appendicular and craniofacial skeletons had a significant survival advantage [hazard ratio (HR) = 0.694, 95% confidence interval (CI) 0.552–0.872; HR = 0.729, 95% CI 0.597–0.889, respectively] over those with axial skeletons as primary tumor sites. Patients with Hodgkin lymphoma, non-Hodgkin lymphoma (NHL)–mature B-cell lymphoma, and NHL-precursor-cell lymphoblastic lymphoma also had a significant OS advantage (HR = 0.392, 95% CI 0.200–0.771; HR = 0.826, 95% CI 0.700–0.973; and HR = 0.453, 95% CI 0.223–0.923, respectively). Patients with Ann Arbor stage III–IV at diagnosis were at higher risk of death than those with stage I–II (HR = 1.348, 95% CI 1.107–1.641). Chemotherapy was an independent favorable prognostic factor (HR = 0.734, 95% CI 0.605–0.890). Conclusions: Primary anatomic site, histology type, higher Ann Arbor stage and chemotherapy were independent prognostic factors. Chemotherapy played a pivotal role in PLB treatment.
- Published
- 2020
- Full Text
- View/download PDF
5. BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib and by promoting mitochondrial pathway-mediated cell apoptosis
- Author
-
Guang Li, Yan-Hua Zheng, Li Xu, Juan Feng, Hai-Long Tang, Cheng Luo, Yan-Ping Song, and Xie-Qun Chen
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Background: Multiple myeloma (MM) is the second most common hematological neoplasm. Wide administration of bortezomib significantly improves the survival of MM patients compared with conventional chemotherapy. Bromodomain-containing protein 4 (BRD4) inhibitors also have been demonstrated to retard cell proliferation and induce cellular apoptosis in various cancers. However, it is unclear whether the BRD4 inhibitor nitroxoline plus bortezomib has a synergistic anti-tumor effect on MM. Methods: Cell viability was determined via 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Cell cycle and cell apoptosis were assessed via flow cytometry. Protein expression levels were determined via western blotting. The expression of apoptosis-related proteins in xenograft tissue were detected by means of immunohistochemistry. Results: Treatment with nitroxoline or bortezomib suppressed cell proliferation, and caused G0/G1 phase arrest and apoptosis in H929 and RPMI8226 cells. Furthermore, nitroxoline intensified the retardation of cell proliferation, as well as further enhanced the G0/G1 phase arrest and apoptosis induced by bortezomib in H929 and RPMI8226 cells. The western blot analysis revealed that nitroxoline or bortezomib treatment markedly diminished the levels of Bcl-2 and cyclin D1, and increased the levels of p21, Bax, cleaved PARP and cleaved caspase-3. Combination of these two agents was observed to result in further marked changes on these levels compared with nitroxoline or bortezomib treatment alone. What is more, in the xenograft tumor model, combinative treatment markedly inhibited tumor growth compared with the single drug treatment. Conclusion: Combination of bortezomib with nitroxoline has a synergistic anti-tumor activity in MM cells and may be a novel treatment method for MM.
- Published
- 2020
- Full Text
- View/download PDF
6. Pulmonary Lymphomatoid Granulomatosis With Hemophagocytic Lymphohistiocytosis as the Initial Manifestation
- Author
-
Li Xu, Xuan Zhang, Ying-Juan Lu, Yan-Hua Zheng, and Guang-Xun Gao
- Subjects
lymphomatiod granulomatosis ,hemophagocytic lymphohistiocytosis ,pathology ,rare lymphoma ,Epstein-Barr virus ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Lymphomatoid granulomatosis (LYG) is an extremely rare angio-centric and angio-destructive B-cell lymphoproliferative disease. Driven by Epstein-Barr virus (EBV), LYG predominantly involves the bilateral lungs. Commonly presenting as multiple nodules in the lung, pulmonary LYG can masquerade as various infectious diseases, vasculitis, lung cancer, or other metastatic neoplasm. It is difficult to be diagnosed and is always neglected by clinicians. No standardized therapeutic regimens for LYG has been established yet now. Hemophagocytic lymphohistiocytosis (HLH), a life-threatening condition caused by abnormal activation of macrophages and T-cells, is characterized by fever, hepatosplenomegaly, pancytopenia, hypercytokinemia, and the presence of hemophagocytosis within the bone marrow, liver, spleen, or other lymphatic tissue. We herein report a 55-year-old man with recurrent fever, severe jaundice, and multiple high-density opacities and nodules in both lungs, who was finally diagnosed with pulmonary LYG (Grade 3) manifested with secondary HLH. Administration of HLH-1994 protocol led to the rapid control of the symptoms caused by HLH. Rituximab-based combination therapy was useful yet LYG (Grade 3) progressed rapidly. This case demonstrates that tissue biopsy is essential for early pathological diagnosis and effective treatment of LYG.
- Published
- 2020
- Full Text
- View/download PDF
7. Correlations between serum hepatitis B surface antigen and hepatitis B core antibody titers and liver fibrosis in treatment-naïve CHB patients
- Author
-
Xing-Li Sun, Lan-xia Qie, Yan-Hua Zheng, Yun-yan Liu, Shun-mao Ma, Huanwei Zheng, De-hua Wang, Er-Hei Dai, Gui-fang Ren, Jun-Qing Li, Min-Ran Li, and Yu-Ling Wang
- Subjects
Adult ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,HBsAg ,Hepatitis B virus ,Liver fibrosis ,Hepatitis b surface antigen ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Hepatitis B, Chronic ,Fibrosis ,Internal medicine ,Medicine ,Humans ,Hepatitis B Antibodies ,lcsh:R5-920 ,Hepatitis B Surface Antigens ,Nucleoside analogue ,business.industry ,virus diseases ,General Medicine ,Middle Aged ,medicine.disease ,Hepatitis B Core Antigens ,Hepatitis b core antibody ,digestive system diseases ,Titer ,Cross-Sectional Studies ,Logistic Models ,HBeAg ,Liver ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Female ,business ,lcsh:Medicine (General) ,medicine.drug - Abstract
Background: Previous studies have revealed that quantitative hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (qAnti-HBc) levels can be used as predictors of treatment response in both interferon-α and nucleoside analogue therapies. Few data have been published regarding the relationship between quantitative HBsAg or Anti-HBc levels and liver fibrosis stages in patients with chronic hepatitis B (CHB). Methods: We conducted a cross-sectional study of treatment-naïve CHB patients. A total of 624 CHB patients were recruited. We assessed the serum HBsAg and qAnti-HBc levels, HBV DNA levels, HBV genotypes, BCP/PC mutations, histological fibrosis staging by Scheuer classification. Results: In HBeAg (+) patients, the S0-1 subjects had significantly higher serum HBsAg and lower qAnti-HBc levels than the S2-4 subjects (both p 0.05). Serum qAnti-HBc levels showed a moderate positive correlation with fibrosis scores (r = 0.383, p
- Published
- 2018
8. Primary lymphoma of bone: a population-based study of 2558 patients
- Author
-
Chun Cao, Yan-Hua Zheng, Guangxun Gao, Chen-Xin Liu, Li Xu, Pan-Pan Wang, and Tian-Qi Xu
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,business.industry ,lcsh:RC633-647.5 ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,Malignancy ,medicine.disease ,survival ,SEER ,Population based study ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Primary lymphoma ,medicine ,therapeutic modality ,primary lymphoma of bone ,prognosis ,business ,Original Research - Abstract
Background: Primary lymphoma of bone (PLB) is an extremely rare malignancy arising in the skeletal system. There is no consensus over the best definition of PLB. Most of the published articles are single-institutional retrospective studies with a limited sample size. The rarity of PLB and discrepancies on diagnostic criteria has resulted in a vague understanding of PLB. Methods We retrospectively analyzed the clinical characteristics and prognostic factors of 2558 PLB patients who were registered in the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2016. Survival rates were calculated using the Kaplan–Meier method. The effects of various factors on survival outcomes were analyzed by using the log-rank test. Univariate and multivariate analyses were conducted by using the Cox proportional hazards model to determine independent prognostic factors. Results: The median follow-up time of all eligible patients was 58 months. There seemed no sex preponderance in PLB incidence. The most involved sites are axial skeletons. The most common histological subtype was diffuse large B-cell lymphoma. The 3-, 5-, 10-, and 20-year overall survival (OS) rates were 70.70%, 65.70%, 54.40% and 39.50%, respectively. PLB patients whose primary tumor sites were appendicular and craniofacial skeletons had a significant survival advantage [hazard ratio (HR) = 0.694, 95% confidence interval (CI) 0.552–0.872; HR = 0.729, 95% CI 0.597–0.889, respectively] over those with axial skeletons as primary tumor sites. Patients with Hodgkin lymphoma, non-Hodgkin lymphoma (NHL)–mature B-cell lymphoma, and NHL-precursor-cell lymphoblastic lymphoma also had a significant OS advantage (HR = 0.392, 95% CI 0.200–0.771; HR = 0.826, 95% CI 0.700–0.973; and HR = 0.453, 95% CI 0.223–0.923, respectively). Patients with Ann Arbor stage III–IV at diagnosis were at higher risk of death than those with stage I–II (HR = 1.348, 95% CI 1.107–1.641). Chemotherapy was an independent favorable prognostic factor (HR = 0.734, 95% CI 0.605–0.890). Conclusions: Primary anatomic site, histology type, higher Ann Arbor stage and chemotherapy were independent prognostic factors. Chemotherapy played a pivotal role in PLB treatment.
- Published
- 2020
9. Pulmonary Lymphomatoid Granulomatosis With Hemophagocytic Lymphohistiocytosis as the Initial Manifestation
- Author
-
Xuan Zhang, Li Xu, Yan-Hua Zheng, Ying-Juan Lu, and Guangxun Gao
- Subjects
0301 basic medicine ,Cancer Research ,Pathology ,medicine.medical_specialty ,Lymphomatoid granulomatosis ,Hepatosplenomegaly ,lymphomatiod granulomatosis ,Case Report ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,rare lymphoma ,hemic and lymphatic diseases ,Medicine ,Epstein-Barr virus ,Hemophagocytic lymphohistiocytosis ,Lung ,business.industry ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Pancytopenia ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,hemophagocytic lymphohistiocytosis ,030220 oncology & carcinogenesis ,pathology ,Pulmonary Lymphomatoid Granulomatosis ,Hemophagocytosis ,medicine.symptom ,business ,Vasculitis - Abstract
Lymphomatoid granulomatosis (LYG) is an extremely rare angio-centric and angio-destructive B-cell lymphoproliferative disease. Driven by Epstein-Barr virus (EBV), LYG predominantly involves the bilateral lungs. Commonly presenting as multiple nodules in the lung, pulmonary LYG can masquerade as various infectious diseases, vasculitis, lung cancer, or other metastatic neoplasm. It is difficult to be diagnosed and is always neglected by clinicians. No standardized therapeutic regimens for LYG has been established yet now. Hemophagocytic lymphohistiocytosis (HLH), a life-threatening condition caused by abnormal activation of macrophages and T-cells, is characterized by fever, hepatosplenomegaly, pancytopenia, hypercytokinemia, and the presence of hemophagocytosis within the bone marrow, liver, spleen, or other lymphatic tissue. We herein report a 55-year-old man with recurrent fever, severe jaundice, and multiple high-density opacities and nodules in both lungs, who was finally diagnosed with pulmonary LYG (Grade 3) manifested with secondary HLH. Administration of HLH-1994 protocol led to the rapid control of the symptoms caused by HLH. Rituximab-based combination therapy was useful yet LYG (Grade 3) progressed rapidly. This case demonstrates that tissue biopsy is essential for early pathological diagnosis and effective treatment of LYG.
- Published
- 2020
10. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials
- Author
-
Hong-Yuan Shen, Na Zhang, Hailong Tang, Juan Feng, Guangxun Gao, Xiequn Chen, Yan-Hua Zheng, and Li Xu
- Subjects
Oncology ,lcsh:Immunologic diseases. Allergy ,medicine.medical_specialty ,Combination therapy ,Immunology ,Review Article ,Dexamethasone ,Disease-Free Survival ,Bortezomib ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Immunology and Allergy ,Humans ,Lenalidomide ,Multiple myeloma ,Randomized Controlled Trials as Topic ,business.industry ,Daratumumab ,Antibodies, Monoclonal ,General Medicine ,medicine.disease ,Combined Modality Therapy ,Thalidomide ,Histone Deacetylase Inhibitors ,Treatment Outcome ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Neoplasm Recurrence, Local ,business ,Multiple Myeloma ,lcsh:RC581-607 ,Progressive disease ,030215 immunology ,medicine.drug - Abstract
During the past decades, agents with novel mechanisms of action, such as monoclonal antibodies (MAbs) and histone deacetylase inhibitors (HDACis) have been applied to treat relapsed or refractory multiple myeloma (RRMM). The treatment outcomes of MAbs versus HDACi in combination with bortezomib or lenalidomide plus dexamethasone remain unknown. We conducted this meta-analysis to compare indirectly the efficacy and safety of MAbs and HDACis in combination with bortezomib or lenalidomide plus dexamethasone. Six trials (eight articles) were included in the meta-analysis with 3270 RRMM patients enrolled. We synthesized hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS), risk ratios (RRs) for complete response (CR),very good partial response (VGPR), overall response (OR), progressive disease plus stable disease (PD + SD) and common at least grade 3 adverse events, and their corresponding 95%confidence intervals (95% CI). Treatment with MAbs in combination with bortezomib or lenalidomide plus dexamethasone resulted in longer PFS (HR 0.83, 95% CI: 0.66–0.98), fewer incidences of at least grade 3 thrombocytopenia (RR 0.35, 95% CI: 0.23–0.53), neutropenia (RR 0.70, 95% CI: 0.51–0.96), and sense of fatigue (RR 0.37, 95% CI: 0.17–0.82) than HDACis. The daratumumab plus bortezomib or lenalidomide and dexamethasone might significantly improve PFS in comparison with HDACis plus bortezomib or lenalidomide and dexamethasone (HR 0.55, 95% CI: 0.40–0.74). In conclusion, MAbs may be superior to HDACis in achieving longer PFS and may be better tolerated when in combination therapy with bortezomib or lenalidomide plus dexamethasone.
- Published
- 2018
11. BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis.
- Author
-
Guang Li, Yan-Hua Zheng, Li Xu, Juan Feng, Hai-Long Tang, Cheng Luo, Yan-Ping Song, and Xie-Qun Chen
- Published
- 2020
- Full Text
- View/download PDF
12. Quantitative hepatitis B core antibody level is associated with inflammatory activity in treatment-naïve chronic hepatitis B patients.
- Author
-
Min-Ran Li, Jian-Hua Lu, Li-Hong Ye, Xing-Li Sun, Yan-Hua Zheng, Zhi-Quan Liu, Hai-Cong Zhang, Yun-Yan Liu, Ying Lv, Yan Huang, Er-Hei Dai, Li, Min-Ran, Lu, Jian-Hua, Ye, Li-Hong, Sun, Xing-Li, Zheng, Yan-Hua, Liu, Zhi-Quan, Zhang, Hai-Cong, Liu, Yun-Yan, and Lv, Ying
- Published
- 2016
- Full Text
- View/download PDF
13. Identification of Serum Biomarkers for Nasopharyngeal Carcinoma by Proteomic Analysis.
- Author
-
Ye-Sheng Wei, Yan-Hua Zheng, Wei-Bo Liang, Jian-Zhong Zhang, Zhi-Hui Yang, Mei-Li Lv, Jing Jia, and Lin Zhang
- Subjects
- *
NASOPHARYNX cancer , *PROTEIN analysis , *MASS spectrometry , *CANCER patients , *IONIZATION (Atomic physics) - Abstract
The article focuses on a study which assessed the feasibility of mass spectrometry-based protein profiling for differentiating patients with nasopharyngeal carcinoma (NPC) from noncancer patients. The study analyzed serum samples from patients diagnosed with NPC and from noncancer controls using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). It concluded that SELDI-TOF-MS combined with a tree analysis model can discriminate NPC from noncancer patients.
- Published
- 2008
- Full Text
- View/download PDF
14. The beneficial effect of α-lipoic acid on spinal cord injury repair in rats is mediated through inhibition of oxidative stress: A transcriptomic analysis.
- Author
-
Bian MM, Xu YM, Zhang L, Yan HZ, Gao JX, Fu GQ, Wang YY, and Lü HZ
- Abstract
Background: Oxidative stress is a crucial factor contributing to the occurrence and development of secondary damage in spinal cord injuries (SCI), ultimately impacting the recovery process. α-lipoic acid (ALA) exhibits potent antioxidant properties, effectively reducing secondary damage and providing neuroprotective benefits. However, the precise mechanism by which ALA plays its antioxidant role remains unknown., Methods: We established a model of moderate spinal cord contusion in rats. Experimental rats were randomly divided into 3 distinct groups: the sham group, the model control group (SCI_Veh), and the ALA treatment group (SCI_ALA). The sham group rats were exposed only to the SC without contusion injury. Rats belonging to SCI_Veh group were not administered any treatment after SCI. Rats of SCI_ALA group were intraperitoneally injected with the corresponding volume of ALA according to body weight for three consecutive days after the surgery. Subsequently, three days after SCI, spinal cord samples were obtained from three groups of rats: the sham group, model control group, and administration group. Thereafter, total RNA was extracted from the samples and the expression of three sets of differential genes was analyzed by transcriptome sequencing technology. Real-time PCR was used to verify the sequencing results. The impact of ALA on oxidative stress in rats following SCI was assessed by measuring their total antioxidant capacity and hydrogen peroxide (H
2 O2 ) content. The effects of ALA on rat recovery following SCI was investigated through Beattie and Bresnahan (BBB) score and footprint analysis., Results: The findings from the transcriptome sequencing analysis revealed that the model control group had 2975 genes with altered expression levels when compared to the ALA treatment group. Among these genes, 1583 were found to be upregulated while 1392 were down-regulated. Gene ontology (GO) displayed significant enrichment in terms of functionality, specifically in oxidative phosphorylation, oxidoreductase activity, and signaling receptor activity. The Kyoto encyclopedia of genes and genomes (KEGG) pathway was enriched in oxidative phosphorylation, glutathione metabolism and cell cycle. ALA was found to have multiple benefits for rats after SCI, including increasing their antioxidant capacity and reducing H2 O2 levels. Additionally, it was effective in improving motor function (such as 7 days after SCI, the BBB score for SCI_ALA was 8.400 ± 0.937 compared to 7.050 ± 1.141 for SCI_Veh) and promoting histological recovery after SCI (The results of HE demonstrated that the percentage of damage area in was 44.002 ± 6.680 in the SCI_ALA and 57.215 ± 3.964 in the SCI_Veh at the center of injury.). The sequence data from this study has been deposited into Sequence Read Archive (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE242507)., Conclusion: Overall, the findings of this study confirmed the beneficial effects of ALA on recovery in SCI rats through transcriptome sequencing, behavioral, as well histology analyses.- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.